We find that this engineered oncolytic virus is capable of activating neoantigen-specific T cell responses by the likely synergistic action of viral replication, GM-CSF stimulation, and PD-L1 inhibition on tumor cells and immune cells, providing a novel oncolytic immunotherapy. This evidence concerns the gene CSF2 and neoplasm.